Natalie Dimier

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings, Franck Morschhauser, Gloria Iacoboni et al. · Journal of Clinical Oncology · 2021 · 392 citations · Full text

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Laurie H. Sehn, Neil Chua, Greg Dueck et al. · The Lancet Oncology · 2016 · 336 citations

Lymphoid Neoplasia, Oncology, Cancer Treatment +3

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial

Nicole Basset‐Séguin, Axel Hauschild, Rainer Kunstfeld et al. · European Journal of Cancer · 2017 · 281 citations · Full text

A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL

Natalie Dimier, Paul Delmar, Carol Ward et al. · Blood · 2017 · 78 citations · Full text

Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma

Ann-Marie E Bröske, Koorosh Korfi, Anton Belousov et al. · Blood Advances · 2021 · 66 citations · Full text